Literature DB >> 24239105

Engineered T cells for cancer treatment.

Usanarat Anurathapan1, Ann M Leen1, Malcolm K Brenner1, Juan F Vera2.   

Abstract

Adoptively transferred T cells have the capacity to traffic to distant tumor sites, infiltrate fibrotic tissue and kill antigen-expressing tumor cells. Various groups have investigated different genetic engineering strategies designed to enhance tumor specificity, increase T cell potency, improve proliferation, persistence or migratory capacity and increase safety. This review focuses on recent developments in T cell engineering, discusses the clinical application of these engineered cell products and outlines future prospects for this therapeutic modality.
Copyright © 2014 International Society for Cellular Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CAR T cells; cancer treatment; genetic modification of T cells; immunotherapy

Mesh：

Substances：

Year:  2013        PMID： 24239105      PMCID： PMC4013208          DOI： 10.1016/j.jcyt.2013.10.002

Source DB:  PubMed          Journal:  Cytotherapy        ISSN： 1465-3249            Impact factor:   5.414


  230 in total

1.  Ectopic human telomerase catalytic subunit expression maintains telomere length but is not sufficient for CD8+ T lymphocyte immortalization.

Authors:  M Migliaccio; M Amacker; T Just; P Reichenbach; D Valmori; J C Cerottini; P Romero; M Nabholz
Journal:  J Immunol       Date:  2000-11-01       Impact factor: 5.422

2.  Chimeric T cells for adoptive immunotherapy of cancer: using what have we learned to plan for the future.

Authors:  Stefan Peinert; Michael H Kershaw; H Miles Prince
Journal:  Immunotherapy       Date:  2009-11       Impact factor: 4.196

3.  Single-pass, closed-system rapid expansion of lymphocyte cultures for adoptive cell therapy.

Authors:  Jacob A Klapper; Armen A Thomasian; Douglas M Smith; Gayle C Gorgas; John R Wunderlich; Franz O Smith; Brian S Hampson; Steven A Rosenberg; Mark E Dudley
Journal:  J Immunol Methods       Date:  2009-04-21       Impact factor: 2.303

4.  Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis.

Authors:  Gianpietro Dotti; Barbara Savoldo; Martin Pule; Karin C Straathof; Ettore Biagi; Eric Yvon; Stephane Vigouroux; Malcolm K Brenner; Cliona M Rooney
Journal:  Blood       Date:  2005-02-15       Impact factor: 22.113

5.  T cells redirected by a CD3ζ chimeric antigen receptor can establish self-antigen-specific tumour protection in the long term.

Authors:  M Chmielewski; G Rappl; A A Hombach; H Abken
Journal:  Gene Ther       Date:  2012-03-01       Impact factor: 5.250

6.  Expression in cytotoxic T lymphocytes of a single-chain anti-carcinoembryonic antigen antibody. Redirected Fas ligand-mediated lysis of colon carcinoma.

Authors:  P K Darcy; M H Kershaw; J A Trapani; M J Smyth
Journal:  Eur J Immunol       Date:  1998-05       Impact factor: 5.532

7.  Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.

Authors:  James N Kochenderfer; Wyndham H Wilson; John E Janik; Mark E Dudley; Maryalice Stetler-Stevenson; Steven A Feldman; Irina Maric; Mark Raffeld; Debbie-Ann N Nathan; Brock J Lanier; Richard A Morgan; Steven A Rosenberg
Journal:  Blood       Date:  2010-07-28       Impact factor: 22.113

8.  Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy.

Authors:  Richard A Morgan; Nachimuthu Chinnasamy; Daniel Abate-Daga; Alena Gros; Paul F Robbins; Zhili Zheng; Mark E Dudley; Steven A Feldman; James C Yang; Richard M Sherry; Giao Q Phan; Marybeth S Hughes; Udai S Kammula; Akemi D Miller; Crystal J Hessman; Ashley A Stewart; Nicholas P Restifo; Martha M Quezado; Meghna Alimchandani; Avi Z Rosenberg; Avindra Nath; Tongguang Wang; Bibiana Bielekova; Simone C Wuest; Nirmala Akula; Francis J McMahon; Susanne Wilde; Barbara Mosetter; Dolores J Schendel; Carolyn M Laurencot; Steven A Rosenberg
Journal:  J Immunother       Date:  2013-02       Impact factor: 4.456

9.  CD20 is a molecular target for scFvFc:zeta receptor redirected T cells: implications for cellular immunotherapy of CD20+ malignancy.

Authors:  M Jensen; G Tan; S Forman; A M Wu; A Raubitschek
Journal:  Biol Blood Marrow Transplant       Date:  1998       Impact factor: 5.742

Review 10.  Monoclonal T-cell receptors: new reagents for cancer therapy.

Authors:  Hans J Stauss; Michela Cesco-Gaspere; Sharyn Thomas; Daniel P Hart; Shao-An Xue; Angelika Holler; Graham Wright; Mario Perro; Ann-Margaret Little; Constantina Pospori; Judy King; Emma C Morris
Journal:  Mol Ther       Date:  2007-07-17       Impact factor: 11.454
View more
  7 in total

Review 1.  Towards a commercial process for the manufacture of genetically modified T cells for therapy.

Authors:  A D Kaiser; M Assenmacher; B Schröder; M Meyer; R Orentas; U Bethke; B Dropulic
Journal:  Cancer Gene Ther       Date:  2015-01-23       Impact factor: 5.987

Review 2.  Advancing Immune and Cell-Based Therapies Through Imaging.

Authors:  Vladimir Ponomarev
Journal:  Mol Imaging Biol       Date:  2017-06       Impact factor: 3.488

3.  Immunological Synapse Predicts Effectiveness of Chimeric Antigen Receptor Cells.

Authors:  Wei Xiong; Yuhui Chen; Xi Kang; Zhiying Chen; Peilin Zheng; Yi-Hsin Hsu; Joon Hee Jang; Lidong Qin; Hao Liu; Gianpietro Dotti; Dongfang Liu
Journal:  Mol Ther       Date:  2018-03-02       Impact factor: 11.454

4.  In vitro machine learning-based CAR T immunological synapse quality measurements correlate with patient clinical outcomes.

Authors:  Alireza Naghizadeh; Wei-Chung Tsao; Jong Hyun Cho; Hongye Xu; Mohab Mohamed; Dali Li; Wei Xiong; Dimitri Metaxas; Carlos A Ramos; Dongfang Liu
Journal:  PLoS Comput Biol       Date:  2022-03-18       Impact factor: 4.475

Review 5.  Chimeric antigen receptor for adoptive immunotherapy of cancer: latest research and future prospects.

Authors:  Huan Shi; Meili Sun; Lin Liu; Zhehai Wang
Journal:  Mol Cancer       Date:  2014-09-21       Impact factor: 27.401

Review 6.  Immune Response Against Head and Neck Cancer: Biological Mechanisms and Implication on Therapy.

Authors:  Francesco Perri; Franco Ionna; Francesco Longo; Giuseppina Della Vittoria Scarpati; Carmine De Angelis; Alessandro Ottaiano; Gerardo Botti; Francesco Caponigro
Journal:  Transl Oncol       Date:  2019-12-21       Impact factor: 4.243

7.  Analysis and Augmentation of the Immunologic Bystander Effects of CAR T Cell Therapy in a Syngeneic Mouse Cancer Model.

Authors:  Astero Klampatsa; Michael S Leibowitz; Jing Sun; Maria Liousia; Evguenia Arguiri; Steven M Albelda
Journal:  Mol Ther Oncolytics       Date:  2020-07-15       Impact factor: 7.200
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.